Search

Your search keyword '"Seghatchian, Jerard"' showing total 244 results

Search Constraints

Start Over You searched for: Author "Seghatchian, Jerard" Remove constraint Author: "Seghatchian, Jerard" Journal transfusion and apheresis science official journal of the world apheresis association official journal of the european society for haemapheresis Remove constraint Journal: transfusion and apheresis science official journal of the world apheresis association official journal of the european society for haemapheresis
244 results on '"Seghatchian, Jerard"'

Search Results

1. Towards personalized and rational use of immunoglobulins amid expanding indications and shortages.

5. Spotlights on the trends in performance assessment of qualitative in vitro diagnostic medical devices in transfusion medicine.

11. Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient's safety and survival outcome:A systematic narrative appraisal of where we are now!

12. Cryopreservation of apheresis platelets treated with riboflavin and UV light.

15. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes.

16. Blood transfusion in autoimmune rheumatic diseases.

18. Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron.

20. Editorial: Time to explore the missing links: the cross-talk between COVID infection and cancer cells; lingering questions on the longitudinal efficacy of the front line immunotherapies against unpredictable "Omicron ghosts" and insights from CAR-T cell therapy pointing toward better clinical outcomes.

21. SARS-CoV-2 and cancer: the intriguing and informative cross-talk.

22. Platelet and extracellular vesicles in COVID-19 infection and its vaccines.

23. Editorial: Time to explore the missing links: from activated platelets and platelet extracellular vesicles in SARS-CoV-2 infection, through heterogeneity in the host physiological, immuno-inflammatory and haemostatic responses to mRNA-based vaccine or infection induced polyclonal neutralizing antibodies and passive immunity.

27. Spotlight on the latest trends on CoV-2 Alpha and Delta variants in the UK; Targeting blood donor population for assessing the effect of the mRNA vaccines on the seroprevalence of CoV-2 Delta variant antibodies and reflections on the management of alloimmunisation in transfused patients with constitutional anaemias in Norway.

29. Exploratory spotlights on the proteome of extracellular vesicles in red blood cell units prepared by the same donors revealed that leukoreduction may matter for the quality and safety of transfusion therapy: Back to basics for research topics that might begin tomorrow's realities.

30. Facts and challenges on global deployment of vaccines for the immunotherapy of the evolving SARS Cov-2 variants: What a new year, with a fast spreading South African and the most fearful Brazilian variants, as the unwanted gifts, imposing enormous crises to surmount.

33. An Overview of Current Position on Cell Therapy in Transfusion Science and Medicine: From Fictional Promises to Factual and Perspectives from Red Cell Substitution to Stem Cell Therapy.

34. Assessment of extracellular vesicles using IFC for application in transfusion medicine.

35. Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!

37. An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research.

38. Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity.

39. Spotlight on the current perspectives on applications of human blood cell culture and organoids: Introductory remarks.

41. The secrets of human stem cell-derived transfusable RBC for targeted large-scale production and clinical applications: A fresh look into what we need most and lessons to be learned.

43. In vitro platelet production for transfusion purposes: Where are we now?

44. Opportunities for standardization of cold stored, low-titre group O WB products.

45. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?

48. Emergency Supply Policy of Cryopreserved RBC and PLT: The Czech Republic Concept.

50. Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview.

Catalog

Books, media, physical & digital resources